Pediatrix Medical Group (MD) Financials

$14.32 +1.37 (+10.54%)

As of 03:00 PM Eastern

Annual Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	317	336	325	320	269	-1,498	-796	131	66	-60	-99
Consolidated Net Income / (Loss)	317	336	325	320	269	-1,498	-796	131	66	-60	-99
Net Income / (Loss) Continuing Operations	317	336	325	305	122	42	-9.58	108	63	-60	-99
Total Pre-Tax Income	509	540	514	386	166	59	7.15	135	81	-48	-101
Total Operating Income	513	558	572	455	248	172	98	203	173	7.32	-69
Total Gross Profit	2,439	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013
Total Revenue	2,439	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013
Operating Revenue	2,439	2,780	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1,926	2,222	2,611	2,798	1,475	1,608	1,636	1,723	1,799	1,987	2,082
Selling, General & Admin Expense	1,791	2,059	2,404	2,613	1,358	1,425	1,443	1,561	1,615	1,676	1,679
Depreciation Expense	46	64	89	79	24	26	28	32	36	36	32
Other Operating Expenses / (Income)	89	98	118	106	92	96	91	100	122	125	127
Impairment Charge	-	-	-	0.00	-	-	-	0.00	0.00	148	178
Restructuring Charge	-	-	-	0.00	0.00	61	74	22	27	2.22	64
Total Other Income / (Expense), net	-4.38	-18	-58	-69	-82	-113	-91	-68	-91	-56	-33
Interest Expense	8.89	23	63	75	93	119	110	83	97	42	41
Interest & Investment Income	4.51	4.97	5.20	5.34	11	5.96	19	16	5.39	6.40	8.12
Other Income / (Expense), net	-	-	-	-	-	0.00	-	0.00	0.00	-20	0.00
Income Tax Expense	191	204	189	80	45	17	17	27	19	12	-2.27
Net Income / (Loss) Discontinued Operations	-	-	-	15	147	-1,540	-787	23	3.77	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.08	-0.63	-0.32	-	-	0.00	0.00	-0.03	-0.00	0.00	0.00
Basic Earnings per Share	$3.22	$3.61	$3.52	$3.47	$2.95	($17.94)	($9.55)	$1.54	$0.79	($0.73)	($1.19)
Weighted Average Basic Shares Outstanding	98.59M	93.08M	92.42M	92.43M	91.10M	83.50M	83.40M	84.83M	83.47M	82.20M	83.33M
Diluted Earnings per Share	$3.18	$3.58	$3.49	$3.45	$2.93	($17.83)	($9.55)	$1.53	$0.79	($0.73)	($1.19)
Weighted Average Diluted Shares Outstanding	99.89M	93.96M	93.11M	92.96M	91.61M	84.01M	83.40M	85.83M	84.12M	82.20M	83.33M
Weighted Average Basic & Diluted Shares Outstanding	98.50M	93.20M	93.79M	92.30M	91.10M	84.28M	85.63M	86.47M	83.03M	84.12M	85.83M

This table shows Pediatrix Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	31	30	15	28	21	-125	4.10	-153	21	28
Consolidated Net Income / (Loss)	31	30	14	28	21	-124	4.04	-153	19	30
Net Income / (Loss) Continuing Operations	29	24	14	28	21	-124	4.04	-153	19	30
Total Pre-Tax Income	39	28	21	39	31	-139	7.82	-168	25	33
Total Operating Income	47	36	30	48	40	-111	16	-158	34	39
Total Gross Profit	490	514	491	501	507	496	495	504	511	502
Total Revenue	490	514	491	501	507	496	495	504	511	502
Operating Revenue	490	514	491	501	507	496	495	504	511	502
Total Operating Expenses	443	478	461	452	466	608	479	662	477	463
Selling, General & Admin Expense	401	418	421	412	426	417	429	414	423	413
Depreciation Expense	8.96	9.14	8.95	8.95	9.21	9.06	10	8.79	6.25	6.87
Other Operating Expenses / (Income)	32	31	31	31	31	32	31	43	30	24
Restructuring Charge	0.98	20	0.00	0.00	0.00	2.22	8.48	14	19	24
Total Other Income / (Expense), net	-8.53	-8.21	-9.33	-9.55	-9.44	-27	-8.07	-10	-8.59	-5.96
Interest Expense	9.52	9.95	10	11	10	10	11	10	10	9.71
Interest & Investment Income	0.99	1.74	1.06	1.68	0.93	2.72	2.53	0.30	1.53	3.75
Income Tax Expense	10	3.82	6.51	11	9.44	-15	3.79	-15	5.79	2.85
Basic Earnings per Share	$0.37	$0.35	$0.17	$0.34	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37
Weighted Average Basic Shares Outstanding	82.13M	83.47M	81.89M	82.40M	82.54M	82.20M	82.86M	83.33M	83.89M	83.33M
Diluted Earnings per Share	$0.37	$0.35	$0.17	$0.34	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37
Weighted Average Diluted Shares Outstanding	82.78M	84.12M	82.32M	82.66M	82.95M	82.20M	83.28M	83.33M	84.52M	83.33M
Weighted Average Basic & Diluted Shares Outstanding	83.07M	83.03M	83.76M	83.94M	84.02M	84.12M	84.15M	85.87M	85.88M	85.83M

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	17	3.64	4.13	25	0.33	161	1,016	-736	-378	63	157
Net Cash From Operating Activities	423	369	444	511	314	358	205	77	167	137	207
Net Cash From Continuing Operating Activities	423	369	444	483	59	74	154	114	182	146	217
Net Income / (Loss) Continuing Operations	317	336	325	305	122	42	-9.58	108	63	-60	-99
Consolidated Net Income / (Loss)	317	336	325	320	269	-1,498	-796	131	66	-60	-99
Net Income / (Loss) Discontinued Operations	-	-	-	15	147	-1,540	-787	23	3.77	0.00	0.00
Depreciation Expense	46	64	89	79	24	26	28	32	36	36	32
Amortization Expense	1.23	1.54	4.82	5.51	4.57	5.67	7.16	4.34	1.77	1.24	0.95
Non-Cash Adjustments To Reconcile Net Income	26	31	31	51	34	40	39	38	73	177	197
Changes in Operating Assets and Liabilities, net	32	-64	-5.66	42	-125	-40	89	-55	9.06	-8.39	86
Net Cash From Discontinued Operating Activities	-	-	-	28	255	284	51	-37	-15	-8.76	-11
Net Cash From Investing Activities	-504	-848	-821	-577	-143	102	816	-53	-57	-48	-35
Net Cash From Continuing Investing Activities	-504	-848	-821	-553	-85	-50	-58	-55	-57	-48	-35
Purchase of Property, Plant & Equipment	-18	-27	-39	-26	-17	-19	-29	-32	-30	-33	-22
Acquisitions	-479	-819	-762	-531	-65	47	-2.23	-30	-28	-6.67	-8.17
Purchase of Investments	-27	-34	-61	-28	-16	-35	-62	-35	-17	-32	-65
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	1.08	25	1.38	0.81	6.84
Sale and/or Maturity of Investments	21	32	41	25	14	51	33	16	17	23	52
Net Cash From Financing Activities	98	483	382	90	-171	-393	-4.16	-760	-488	-26	-14
Net Cash From Continuing Financing Activities	98	483	382	90	-169	-384	-2.91	-760	0.00	0.00	0.00
Repayment of Debt	-1,218	-2,172	-1,512	-2,704	-2,102	-1,996	-528	-759	-1,882	-495	-248
Repurchase of Common Equity	-488	-235	-62	-70	-302	-145	-8.49	-4.72	-89	-0.92	-1.70
Issuance of Debt	1,755	2,872	1,940	2,846	2,224	1,747	528	0.00	1,480	470	236
Issuance of Common Equity	44	20	22	24	16	11	7.25	6.85	5.40	4.91	3.64
Other Financing Activities, net	5.72	-1.27	-6.50	-5.45	-5.26	-1.39	-1.16	-3.00	-2.92	-4.44	-4.06
Net Cash From Discontinued Financing Activities	-	-	-	-0.61	-1.36	-8.96	-1.25	0.00	0.00	0.00	0.00
Cash Interest Paid	7.32	20	60	74	83	95	110	87	116	42	40
Cash Income Taxes Paid	162	181	176	75	185	86	-28	55	27	31	4.67

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-5.42	1.16	-3.70	-0.28	15	52	-65	11	84	126
Net Cash From Operating Activities	83	99	-101	89	80	69	-125	107	92	133
Net Cash From Continuing Operating Activities	88	102	-101	93	81	73	-123	109	96	135
Net Income / (Loss) Continuing Operations	29	24	14	28	21	-124	4.04	-153	19	30
Consolidated Net Income / (Loss)	31	30	14	28	21	-124	4.04	-153	19	30
Depreciation Expense	8.96	9.14	8.95	8.95	9.21	9.06	10	8.79	6.25	6.87
Amortization Expense	0.49	0.42	0.39	0.34	0.28	0.22	0.20	0.24	0.26	0.25
Non-Cash Adjustments To Reconcile Net Income	3.32	5.76	2.62	2.62	2.46	170	1.80	194	3.84	-3.06
Changes in Operating Assets and Liabilities, net	47	63	-127	52	48	18	-139	59	66	100
Net Cash From Discontinued Operating Activities	-5.02	-3.61	-0.27	-3.55	-1.18	-3.75	-2.60	-2.39	-3.89	-1.80
Net Cash From Investing Activities	-6.09	-11	-11	-10	-14	-12	-16	-13	-4.34	-1.94
Net Cash From Continuing Investing Activities	-	-57	0.00	-22	-14	-12	0.00	-29	-4.34	-1.94
Purchase of Property, Plant & Equipment	-6.95	-9.06	-7.00	-8.13	-9.15	-9.04	-5.33	-6.96	-6.29	-3.44
Purchase of Investments	-1.96	-2.41	-9.55	-8.21	-8.72	-5.42	-17	-23	-14	-10
Sale of Property, Plant & Equipment	0.96	-0.78	0.00	-	-	0.69	0.00	-	-	4.48
Sale and/or Maturity of Investments	1.85	1.00	6.87	5.95	3.75	6.35	14	17	14	7.17
Net Cash From Financing Activities	-83	-86	109	-79	-51	-4.75	76	-83	-3.07	-4.96
Net Cash From Continuing Financing Activities	-83	401	109	-79	-51	21	76	-83	-3.07	9.52
Repayment of Debt	-261	-241	-107	-285	-100	-3.45	-94	-148	6.22	-12
Repurchase of Common Equity	-21	-1.47	-0.78	-0.01	-0.13	-	-0.89	-0.01	-0.16	-0.64
Issuance of Common Equity	1.38	1.18	1.10	1.59	1.19	1.04	0.86	1.15	0.90	0.73
Other Financing Activities, net	-0.91	-0.74	-0.70	-0.70	-0.70	-2.33	-0.69	-0.70	-10	7.37

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	3,608	4,547	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153
Total Current Assets	467	528	587	627	660	732	1,549	841	428	483	640
Cash & Equivalents	48	52	56	60	25	108	1,124	387	9.82	73	230
Short-Term Investments	6.04	8.85	11	10	22	75	105	100	93	104	119
Accounts Receivable	352	445	495	504	507	434	242	302	297	272	260
Prepaid Expenses	7.04	9.64	11	16	17	17	17	19	15	14	13
Current Deferred & Refundable Income Taxes	46	-	-	-	-	-	0.00	14	0.00	7.57	13
Other Current Assets	7.90	13	14	37	17	12	62	19	13	12	5.09
Plant, Property, & Equipment, net	66	84	103	124	90	73	76	70	73	76	39
Total Noncurrent Assets	3,075	3,936	4,649	5,117	5,187	3,342	1,722	1,812	1,847	1,661	1,474
Goodwill	2,776	3,366	3,845	4,284	4,061	1,480	1,478	1,505	1,532	1,384	1,243
Intangible Assets	198	424	669	640	313	29	27	22	18	21	12
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	22	87	54	88	106	103	104
Other Noncurrent Operating Assets	37	82	57	112	81	105	163	196	190	152	116
Total Liabilities & Shareholders' Equity	3,608	4,547	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153
Total Liabilities	1,343	2,109	2,579	2,801	2,850	2,647	2,600	1,826	1,456	1,371	1,388
Total Current Liabilities	416	429	449	531	503	542	444	427	427	389	434
Short-Term Debt	10	12	22	1.40	0.25	-	-	2.49	15	15	21
Accounts Payable	381	396	408	438	449	411	423	394	374	351	399
Current Deferred & Payable Income Tax Liabilities	25	21	19	92	31	6.04	0.00	11	16	2.16	2.17
Other Current Liabilities	-	-	-	-	0.00	18	21	20	22	21	13
Total Noncurrent Liabilities	926	1,681	2,130	2,269	2,347	2,105	2,156	1,398	1,029	982	954
Long-Term Debt	558	1,263	1,684	1,851	1,974	1,730	1,743	0.00	636	618	597
Noncurrent Deferred & Payable Income Tax Liabilities	160	189	228	148	96	56	62	41	34	34	34
Other Noncurrent Operating Liabilities	208	229	218	270	241	272	352	1,357	359	329	322
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,266	2,438	2,761	3,066	3,088	1,499	748	897	892	849	765
Total Preferred & Common Equity	2,265	2,438	2,761	3,066	3,088	1,499	747	896	892	849	765
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,265	2,438	2,761	3,066	3,088	1,499	747	896	892	849	765
Common Stock	888	927	975	1,018	994	989	1,030	1,051	984	1,001	1,015
Retained Earnings	1,377	1,510	1,786	2,048	2,094	510	-286	-155	-89	-149	-249
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	0.08	3.53	1.32	-3.74	-2.21	-1.07

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	2,332	2,320	2,306	2,326	2,168	1,995	2,077
Total Current Assets	424	409	398	421	427	429	528
Cash & Equivalents	8.67	6.12	5.85	21	8.00	19	104
Short-Term Investments	91	97	98	104	107	114	117
Accounts Receivable	294	279	271	277	284	274	287
Prepaid Expenses	9.66	15	12	11	13	12	10
Current Deferred & Refundable Income Taxes	9.73	-	-	-	5.19	0.00	1.20
Other Current Assets	9.90	12	10	7.87	9.58	9.94	9.48
Plant, Property, & Equipment, net	72	73	73	75	74	48	42
Total Noncurrent Assets	1,837	1,839	1,834	1,831	1,667	1,518	1,507
Goodwill	1,532	1,532	1,532	1,532	1,393	1,239	1,239
Intangible Assets	20	17	17	15	19	10	13
Noncurrent Deferred & Refundable Income Taxes	98	103	102	103	102	124	119
Other Noncurrent Operating Assets	187	119	184	180	83	145	135
Total Liabilities & Shareholders' Equity	2,332	2,320	2,306	2,326	2,168	1,995	2,077
Total Liabilities	1,473	1,410	1,363	1,358	1,312	1,289	1,344
Total Current Liabilities	352	284	320	350	247	310	373
Short-Term Debt	15	15	15	15	16	18	19
Accounts Payable	306	227	278	303	207	267	333
Current Deferred & Payable Income Tax Liabilities	7.66	22	6.15	11	2.80	6.33	3.32
Other Current Liabilities	23	21	22	22	21	19	17
Total Noncurrent Liabilities	1,122	1,126	1,043	1,008	1,065	979	971
Long-Term Debt	731	114	666	622	80	0.00	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	40	33	38	41	34	31	36
Other Noncurrent Operating Liabilities	351	979	339	345	951	948	936
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	859	910	942	968	856	706	732
Total Preferred & Common Equity	859	910	942	968	856	706	732
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	859	910	942	968	856	706	732
Common Stock	981	988	992	997	1,004	1,007	1,012
Retained Earnings	-119	-75	-47	-25	-145	-298	-279
Accumulated Other Comprehensive Income / (Loss)	-4.10	-3.13	-3.52	-3.52	-2.15	-1.95	-0.21

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.23%	13.99%	14.50%	2.21%	-47.04%	3.29%	-2.57%	10.22%	3.18%	1.15%	0.92%
EBITDA Growth	13.84%	11.32%	6.76%	-19.00%	-48.58%	-26.67%	-34.24%	79.01%	-12.24%	-88.23%	-243.68%
EBIT Growth	13.46%	8.75%	2.48%	-20.43%	-45.40%	-30.85%	-42.87%	106.78%	-14.90%	-107.34%	-441.94%
NOPAT Growth	13.11%	8.45%	4.09%	-0.25%	-49.59%	-32.09%	-206.65%	223.21%	-18.06%	-96.14%	-1,038.57%
Net Income Growth	13.08%	5.83%	-3.31%	-1.30%	-16.15%	-657.54%	46.82%	116.44%	-49.34%	-191.07%	-64.00%
EPS Growth	14.39%	12.58%	-2.51%	-1.15%	-15.07%	-708.53%	46.44%	116.02%	-48.37%	-192.41%	-63.01%
Operating Cash Flow Growth	4.25%	-12.76%	20.36%	15.23%	-38.65%	14.03%	-42.80%	-62.50%	117.55%	-17.74%	50.43%
Free Cash Flow Firm Growth	-208.28%	-333.50%	29.51%	76.42%	851.15%	348.77%	-97.31%	1,178.17%	-188.48%	115.68%	58.53%
Invested Capital Growth	19.39%	32.12%	20.39%	10.36%	-9.95%	-65.71%	-14.31%	-67.34%	249.41%	-9.39%	-20.74%
Revenue Q/Q Growth	3.53%	3.39%	2.88%	-3.70%	-47.34%	73.79%	41.00%	4.48%	0.78%	-0.86%	0.30%
EBITDA Q/Q Growth	4.05%	2.58%	-0.10%	-10.67%	-44.13%	114.35%	58.31%	16.32%	-12.89%	-87.15%	80.70%
EBIT Q/Q Growth	3.46%	1.80%	-1.41%	-8.50%	-41.80%	58.25%	91.77%	21.35%	-15.62%	-108.19%	68.69%
NOPAT Q/Q Growth	3.35%	2.09%	-2.64%	18.80%	-52.48%	62.32%	-467.16%	23.58%	-11.90%	-95.54%	68.69%
Net Income Q/Q Growth	3.02%	1.25%	-4.23%	22.12%	-22.03%	-3.52%	-10.19%	584.42%	-21.21%	-164.58%	60.97%
EPS Q/Q Growth	2.25%	0.28%	-4.90%	22.34%	-21.02%	-2.59%	-12.22%	800.00%	-20.20%	-165.18%	25.63%
Operating Cash Flow Q/Q Growth	10.33%	-16.84%	6.43%	14.48%	-12.36%	-4.30%	-41.83%	271.88%	48.40%	-17.65%	44.65%
Free Cash Flow Firm Q/Q Growth	-77.61%	8.64%	1.18%	-660.18%	489.25%	52.66%	-97.74%	244.09%	7.21%	0.48%	-72.02%
Invested Capital Q/Q Growth	2.40%	0.59%	0.16%	3.62%	-11.88%	-51.24%	384.20%	5.86%	-4.30%	-11.84%	94.63%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	22.97%	22.43%	20.92%	16.58%	16.09%	11.43%	7.71%	12.53%	10.65%	1.24%	-1.77%
Operating Margin	21.03%	20.07%	17.96%	13.98%	14.42%	9.65%	5.66%	10.62%	8.76%	0.37%	-3.41%
EBIT Margin	21.03%	20.07%	17.96%	13.98%	14.42%	9.65%	5.66%	10.62%	8.76%	-0.64%	-3.41%
Profit (Net Income) Margin	13.01%	12.08%	10.20%	9.85%	15.59%	-84.15%	-45.93%	6.85%	3.36%	-3.03%	-4.92%
Tax Burden Percent	62.37%	62.20%	63.18%	83.07%	161.62%	-2,547.81%	-11,142.81%	96.83%	81.52%	124.92%	97.76%
Interest Burden Percent	99.15%	96.75%	89.87%	84.78%	66.91%	34.23%	7.28%	66.64%	47.12%	381.41%	147.48%
Effective Tax Rate	37.63%	37.80%	36.82%	20.80%	26.89%	28.20%	234.02%	20.14%	23.11%	0.00%	0.00%
Return on Invested Capital (ROIC)	12.82%	11.01%	9.13%	7.93%	4.01%	4.28%	-9.62%	19.36%	14.34%	0.37%	-4.11%
ROIC Less NNEP Spread (ROIC-NNEP)	11.39%	9.60%	6.43%	5.48%	10.00%	-270.72%	-282.64%	-193.26%	-194.61%	-12.68%	-18.18%
Return on Net Nonoperating Assets (RNNOA)	0.95%	3.27%	3.36%	3.07%	4.72%	-69.58%	-61.28%	-3.44%	-6.92%	-7.31%	-8.16%
Return on Equity (ROE)	13.77%	14.27%	12.49%	11.00%	8.73%	-65.30%	-70.90%	15.93%	7.42%	-6.94%	-12.28%
Cash Return on Invested Capital (CROIC)	-4.86%	-16.67%	-9.37%	-1.92%	14.48%	102.14%	5.79%	120.88%	-96.66%	10.23%	19.02%
Operating Return on Assets (OROA)	15.51%	13.68%	11.56%	8.12%	4.21%	3.41%	2.62%	6.69%	6.81%	-0.56%	-3.14%
Return on Assets (ROA)	9.59%	8.23%	6.57%	5.72%	4.55%	-29.71%	-21.26%	4.31%	2.62%	-2.65%	-4.53%
Return on Common Equity (ROCE)	13.76%	14.27%	12.49%	11.00%	8.73%	-65.30%	-70.90%	15.92%	7.42%	-6.94%	-12.28%
Return on Equity Simple (ROE_SIMPLE)	14.01%	13.77%	11.76%	10.45%	8.70%	-99.91%	-106.56%	14.61%	7.44%	-7.11%	-12.95%
Net Operating Profit after Tax (NOPAT)	320	347	361	360	182	123	-132	162	133	5.12	-48
NOPAT Margin	13.12%	12.48%	11.35%	11.07%	10.54%	6.93%	-7.59%	8.48%	6.73%	0.26%	-2.39%
Net Nonoperating Expense Percent (NNEP)	1.43%	1.41%	2.70%	2.45%	-5.99%	275.00%	273.02%	212.63%	208.95%	13.06%	14.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	8.61%	0.35%	-3.48%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	73.43%	74.08%	75.52%	80.32%	78.80%	80.08%	83.21%	81.67%	81.88%	84.02%	83.42%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	78.97%	79.93%	82.04%	86.02%	85.58%	90.35%	94.34%	90.14%	91.24%	99.63%	103.41%
Earnings before Interest and Taxes (EBIT)	513	558	572	455	248	172	98	203	173	-13	-69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	560	624	666	539	277	203	134	239	210	25	-36
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.93	2.76	2.26	1.63	0.96	1.56	2.81	2.62	1.38	0.92	1.47
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.72	2.42	1.96	1.54	1.71	1.32	1.21	1.23	0.63	0.39	0.56
Price to Earnings (P/E)	20.92	20.04	19.21	15.62	10.98	0.00	0.00	17.96	18.61	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.78%	4.99%	5.21%	6.40%	9.10%	0.00%	0.00%	5.57%	5.37%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.61	2.20	1.81	1.41	1.12	2.64	2.07	4.53	1.24	0.95	1.35
Enterprise Value to Revenue (EV/Rev)	2.91	2.84	2.45	2.06	2.78	2.19	1.51	0.98	0.90	0.62	0.69
Enterprise Value to EBITDA (EV/EBITDA)	12.66	12.65	11.72	12.44	17.27	19.13	19.55	7.80	8.49	50.02	0.00
Enterprise Value to EBIT (EV/EBIT)	13.82	14.14	13.65	14.74	19.28	22.65	26.64	9.21	10.32	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	22.16	22.74	21.60	18.62	26.37	31.55	0.00	11.53	13.43	241.38	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	16.78	21.40	17.58	13.11	15.26	10.88	12.78	24.34	10.68	9.01	6.76
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	7.30	1.32	33.04	1.85	0.00	8.82	6.28
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.25	0.52	0.62	0.60	0.64	1.15	2.33	0.00	0.73	0.75	0.81
Long-Term Debt to Equity	0.25	0.52	0.61	0.60	0.64	1.15	2.33	0.00	0.71	0.73	0.78
Financial Leverage	0.08	0.34	0.52	0.56	0.47	0.26	0.22	0.02	0.04	0.58	0.45
Leverage Ratio	1.44	1.73	1.90	1.92	1.92	2.20	3.34	3.69	2.84	2.62	2.71
Compound Leverage Factor	1.42	1.68	1.71	1.63	1.28	0.75	0.24	2.46	1.34	10.01	4.00
Debt to Total Capital	20.07%	34.34%	38.19%	37.66%	39.00%	53.58%	69.97%	0.28%	42.21%	42.72%	44.67%
Short-Term Debt to Total Capital	0.37%	0.32%	0.49%	0.03%	0.01%	0.00%	0.00%	0.28%	0.97%	1.01%	1.49%
Long-Term Debt to Total Capital	19.70%	34.01%	37.70%	37.64%	39.00%	53.58%	69.97%	0.00%	41.25%	41.72%	43.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.03%	0.01%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.90%	65.66%	61.81%	62.34%	61.00%	46.42%	30.02%	99.70%	57.79%	57.28%	55.33%
Debt to EBITDA	1.02	2.04	2.56	3.44	7.12	8.51	13.03	0.01	3.10	25.61	-17.38
Net Debt to EBITDA	0.80	1.85	2.34	3.16	6.63	7.61	3.84	-2.02	2.61	18.42	-7.57
Long-Term Debt to EBITDA	1.00	2.02	2.53	3.43	7.12	8.51	13.03	0.00	3.03	25.01	-16.80
Debt to NOPAT	1.78	3.67	4.72	5.14	10.87	14.03	-13.25	0.02	4.91	123.58	-12.84
Net Debt to NOPAT	1.41	3.32	4.32	4.72	10.12	12.55	-3.91	-2.99	4.13	88.90	-5.60
Long-Term Debt to NOPAT	1.75	3.64	4.66	5.14	10.87	14.03	-13.25	0.00	4.79	120.67	-12.41
Altman Z-Score	4.66	3.42	2.90	2.39	1.58	1.32	1.38	1.82	1.54	1.18	1.27
Noncontrolling Interest Sharing Ratio	0.02%	0.03%	0.01%	0.00%	0.00%	0.00%	0.01%	0.03%	0.01%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.12	1.23	1.31	1.18	1.31	1.35	3.49	1.97	1.00	1.24	1.47
Quick Ratio	0.98	1.18	1.25	1.08	1.10	1.14	3.31	1.85	0.94	1.16	1.40
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-121	-526	-370	-87	656	2,945	79	1,012	-895	140	222
Operating Cash Flow to CapEx	2,340.08%	1,361.88%	1,130.24%	1,955.56%	1,832.41%	1,856.41%	738.49%	1,106.20%	589.27%	422.27%	1,360.20%
Free Cash Flow to Firm to Interest Expense	-13.64	-22.74	-5.87	-1.17	7.06	24.76	0.72	12.15	-9.25	3.34	5.46
Operating Cash Flow to Interest Expense	47.54	15.95	7.03	6.86	3.38	3.01	1.85	0.92	1.73	3.26	5.07
Operating Cash Flow Less CapEx to Interest Expense	45.50	14.78	6.41	6.51	3.19	2.85	1.60	0.84	1.43	2.49	4.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.74	0.68	0.64	0.58	0.29	0.35	0.46	0.63	0.78	0.87	0.92
Accounts Receivable Turnover	7.65	6.98	6.77	6.51	3.41	3.78	5.13	7.03	6.59	7.01	7.56
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	38.73	37.15	34.10	28.71	16.11	21.82	23.30	26.12	27.50	26.79	35.06
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	47.71	52.32	53.89	56.05	107.05	96.49	71.17	51.92	55.39	52.07	48.26
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	47.71	52.32	53.89	56.05	107.05	96.49	71.17	51.92	55.39	52.07	48.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,716	3,589	4,320	4,768	4,294	1,472	1,262	412	1,440	1,305	1,034
Invested Capital Turnover	0.98	0.88	0.80	0.72	0.38	0.62	1.27	2.28	2.13	1.45	1.72
Increase / (Decrease) in Invested Capital	441	873	732	448	-475	-2,821	-211	-850	1,028	-135	-271
Enterprise Value (EV)	7,090	7,890	7,802	6,707	4,788	3,891	2,615	1,868	1,783	1,237	1,396
Market Capitalization	6,638	6,739	6,242	5,005	2,951	2,343	2,101	2,352	1,234	781	1,127
Book Value per Share	$22.55	$25.92	$29.48	$32.74	$34.53	$17.78	$8.73	$10.37	$10.73	$10.11	$8.91
Tangible Book Value per Share	($7.07)	($14.39)	($18.72)	($19.83)	($14.39)	($0.11)	($8.85)	($7.29)	($7.93)	($6.62)	($5.70)
Total Capital	2,834	3,713	4,466	4,919	5,062	3,229	2,490	899	1,543	1,482	1,383
Total Debt	569	1,275	1,706	1,853	1,975	1,730	1,743	2.49	651	633	618
Total Long-Term Debt	558	1,263	1,684	1,851	1,974	1,730	1,743	0.00	636	618	597
Net Debt	451	1,151	1,560	1,702	1,837	1,548	514	-485	548	456	269
Capital Expenditures (CapEx)	18	27	39	26	17	19	28	6.94	28	33	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.28	50	93	27	90	7.31	-124	-71	-87	-68	-122
Debt-free Net Working Capital (DFNWC)	61	111	160	97	157	190	1,105	416	16	109	226
Net Working Capital (NWC)	51	99	138	96	157	190	1,105	413	1.01	95	205
Net Nonoperating Expense (NNE)	2.73	11	37	40	-87	1,621	665	31	66	66	51
Net Nonoperating Obligations (NNO)	451	1,151	1,560	1,702	1,206	-27	514	-485	548	456	269
Total Depreciation and Amortization (D&A)	47	66	94	84	29	32	36	36	37	37	33
Debt-free, Cash-free Net Working Capital to Revenue	0.30%	1.82%	2.93%	0.82%	5.23%	0.41%	-7.13%	-3.74%	-4.42%	-3.43%	-6.08%
Debt-free Net Working Capital to Revenue	2.51%	3.99%	5.03%	2.99%	9.14%	10.66%	63.73%	21.75%	0.81%	5.49%	11.23%
Net Working Capital to Revenue	2.08%	3.56%	4.34%	2.94%	9.12%	10.66%	63.73%	21.62%	0.05%	4.74%	10.21%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.22	$3.61	$3.52	$3.47	$2.95	($17.94)	$0.00	$1.54	$0.79	$0.73	($1.19)
Adjusted Weighted Average Basic Shares Outstanding	98.59M	93.08M	92.42M	92.43M	91.10M	83.50M	0.00	84.83M	83.47M	82.20M	83.33M
Adjusted Diluted Earnings per Share	$3.18	$3.58	$3.49	$3.45	$2.93	($17.94)	$0.00	$1.53	$0.79	$0.73	($1.19)
Adjusted Weighted Average Diluted Shares Outstanding	99.89M	93.96M	93.11M	92.96M	91.61M	83.50M	0.00	85.83M	84.12M	82.20M	83.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$3.61	$3.52	$3.47	$2.95	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	96.08M	93.80M	93.79M	93.80M	87.92M	84.28M	0.00	86.47M	83.03M	84.12M	85.83M
Normalized Net Operating Profit after Tax (NOPAT)	320	347	361	360	182	167	120	186	154	110	122
Normalized NOPAT Margin	13.12%	12.48%	11.35%	11.07%	10.54%	9.39%	6.94%	9.71%	7.80%	5.54%	6.05%
Pre Tax Income Margin	20.85%	19.41%	16.14%	11.85%	9.65%	3.30%	0.41%	7.08%	4.13%	-2.42%	-5.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	57.70	24.14	9.06	6.10	2.67	1.44	0.89	2.44	1.79	-0.30	-1.69
NOPAT to Interest Expense	35.98	15.01	5.72	4.83	1.95	1.04	-1.19	1.95	1.37	0.12	-1.18
EBIT Less CapEx to Interest Expense	55.67	22.97	8.44	5.75	2.49	1.28	0.64	2.35	1.49	-1.07	-2.06
NOPAT Less CapEx to Interest Expense	33.95	13.84	5.10	4.48	1.77	0.87	-1.44	1.86	1.08	-0.65	-1.55
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	153.98%	70.02%	19.05%	21.91%	112.48%	-9.70%	-1.07%	3.60%	133.44%	-1.52%	-1.72%

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.62%	3.07%	1.82%	2.99%	3.41%	-3.39%	0.83%	0.74%	0.90%	1.19%
EBITDA Growth	-17.19%	-40.54%	-18.71%	-2.41%	-12.43%	-324.17%	-32.97%	-357.33%	-18.93%	145.41%
EBIT Growth	-19.40%	-47.01%	-23.18%	-3.30%	-15.01%	-409.37%	-47.10%	-425.22%	-16.00%	135.24%
NOPAT Growth	-18.49%	-39.26%	-24.73%	-1.58%	-20.47%	-351.06%	-60.22%	-413.50%	-6.73%	146.04%
Net Income Growth	-0.19%	-37.57%	167.03%	4.22%	-30.39%	-519.05%	-71.60%	-641.07%	-9.12%	124.52%
EPS Growth	2.78%	-36.36%	168.00%	6.25%	-29.73%	-528.57%	-70.59%	-641.18%	-11.54%	124.67%
Operating Cash Flow Growth	36.38%	123.09%	-3.52%	8.07%	-4.07%	-29.83%	-24.09%	20.10%	14.89%	92.07%
Free Cash Flow Firm Growth	-36.71%	-210.66%	102.78%	105.45%	104.87%	105.73%	659.68%	1,216.49%	1,753.56%	436.26%
Invested Capital Growth	286.52%	249.41%	0.70%	-1.74%	-1.64%	-9.39%	-10.55%	-61.10%	-64.10%	-20.74%
Revenue Q/Q Growth	0.80%	4.88%	-4.44%	1.95%	1.21%	-2.01%	-0.27%	1.86%	1.36%	-1.72%
EBITDA Q/Q Growth	-4.02%	-19.78%	-13.61%	46.71%	-13.88%	-305.37%	125.83%	-663.23%	127.13%	15.05%
EBIT Q/Q Growth	-5.52%	-23.95%	-16.64%	61.44%	-16.96%	-376.84%	114.25%	-1,092.47%	121.45%	16.15%
NOPAT Q/Q Growth	-1.82%	-11.51%	-33.72%	70.92%	-20.66%	-379.32%	110.50%	-1,447.10%	123.60%	37.89%
Net Income Q/Q Growth	13.24%	-3.48%	-52.10%	99.08%	-24.37%	-681.02%	103.25%	-3,892.44%	112.70%	56.78%
EPS Q/Q Growth	15.63%	-5.41%	-51.43%	100.00%	-23.53%	-676.92%	225.00%	-3,780.00%	112.50%	60.87%
Operating Cash Flow Q/Q Growth	1.12%	18.43%	-202.26%	188.24%	-10.24%	-13.37%	-280.83%	185.41%	-14.13%	44.83%
Free Cash Flow Firm Q/Q Growth	5.26%	7.73%	101.41%	341.41%	-15.36%	8.69%	-84.17%	664.94%	19.17%	-68.55%
Invested Capital Q/Q Growth	-2.69%	-4.30%	-35.00%	62.34%	-2.59%	-11.84%	21.99%	-29.40%	-10.10%	94.63%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	11.60%	8.87%	8.02%	11.54%	9.82%	-20.59%	5.33%	-29.49%	7.89%	9.24%
Operating Margin	9.67%	7.01%	6.12%	9.69%	7.95%	-22.46%	3.21%	-31.28%	6.62%	7.82%
EBIT Margin	9.67%	7.01%	6.12%	9.69%	7.95%	-22.46%	3.21%	-31.28%	6.62%	7.82%
Profit (Net Income) Margin	6.27%	5.77%	2.89%	5.65%	4.22%	-25.04%	0.82%	-30.34%	3.80%	6.07%
Tax Burden Percent	79.08%	106.60%	68.59%	72.62%	69.38%	89.51%	51.57%	91.23%	77.04%	91.45%
Interest Burden Percent	82.00%	77.21%	68.95%	80.31%	76.56%	124.54%	49.23%	106.34%	74.60%	84.82%
Effective Tax Rate	25.87%	13.74%	31.41%	27.38%	30.62%	0.00%	48.43%	0.00%	22.96%	8.55%
Return on Invested Capital (ROIC)	14.82%	12.88%	8.91%	9.16%	7.44%	-22.85%	3.73%	-41.55%	10.18%	12.31%
ROIC Less NNEP Spread (ROIC-NNEP)	10.17%	8.40%	-7.43%	8.07%	6.31%	-32.06%	-114.83%	-60.02%	5.91%	10.81%
Return on Net Nonoperating Assets (RNNOA)	1.13%	0.30%	-0.33%	5.77%	4.00%	-18.49%	-0.46%	-16.80%	1.08%	4.85%
Return on Equity (ROE)	15.95%	13.18%	8.59%	14.93%	11.43%	-41.34%	3.28%	-58.35%	11.26%	17.17%
Cash Return on Invested Capital (CROIC)	-101.87%	-96.66%	12.44%	9.73%	9.36%	10.23%	10.60%	73.84%	79.05%	19.02%
Operating Return on Assets (OROA)	7.60%	5.46%	5.20%	8.27%	6.87%	-19.61%	2.86%	-29.12%	6.03%	7.20%
Return on Assets (ROA)	4.93%	4.49%	2.46%	4.82%	3.65%	-21.87%	0.73%	-28.26%	3.47%	5.59%
Return on Common Equity (ROCE)	15.95%	13.18%	8.59%	14.93%	11.43%	-41.34%	3.28%	-58.35%	11.26%	17.17%
Return on Equity Simple (ROE_SIMPLE)	9.80%	0.00%	11.18%	10.92%	9.66%	0.00%	-8.24%	-35.65%	-34.65%	0.00%
Net Operating Profit after Tax (NOPAT)	35	31	21	35	28	-78	8.20	-110	26	36
NOPAT Margin	7.17%	6.05%	4.20%	7.04%	5.52%	-15.72%	1.66%	-21.89%	5.10%	7.15%
Net Nonoperating Expense Percent (NNEP)	4.65%	4.48%	16.34%	1.09%	1.13%	9.21%	118.56%	18.47%	4.26%	1.50%
Return On Investment Capital (ROIC_SIMPLE)	-	2.01%	-	-	-	-5.26%	-	-	-	2.60%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	81.80%	81.27%	85.80%	82.31%	84.05%	83.93%	86.72%	82.17%	82.76%	82.12%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	90.33%	92.99%	93.88%	90.31%	92.05%	122.46%	96.79%	131.28%	93.38%	92.18%
Earnings before Interest and Taxes (EBIT)	47	36	30	48	40	-111	16	-158	34	39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	57	46	39	58	50	-102	26	-149	40	46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.62	1.38	1.36	1.26	1.10	0.92	0.98	0.90	1.36	1.47
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.71	0.63	0.63	0.60	0.53	0.39	0.42	0.32	0.50	0.56
Price to Earnings (P/E)	16.54	18.61	12.10	11.55	11.38	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.05%	5.37%	8.27%	8.66%	8.79%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.35	1.24	1.35	1.16	1.07	0.95	0.98	0.88	1.49	1.35
Enterprise Value to Revenue (EV/Rev)	1.04	0.90	0.64	0.89	0.78	0.62	0.41	0.26	0.40	0.69
Enterprise Value to EBITDA (EV/EBITDA)	8.45	8.49	6.29	8.85	8.20	50.02	25.95	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	9.96	10.32	7.73	10.91	10.20	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	13.53	13.43	10.31	14.46	13.73	241.38	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.12	10.68	7.73	10.39	9.47	9.01	7.29	3.97	5.56	6.76
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	10.89	11.85	11.30	8.82	8.77	0.67	1.00	6.28
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.87	0.73	0.14	0.72	0.66	0.75	0.11	0.03	0.03	0.81
Long-Term Debt to Equity	0.85	0.71	0.13	0.71	0.64	0.73	0.09	0.00	0.00	0.78
Financial Leverage	0.11	0.04	0.04	0.71	0.63	0.58	0.00	0.28	0.18	0.45
Leverage Ratio	2.92	2.84	2.61	2.62	2.55	2.62	2.54	2.61	2.59	2.71
Compound Leverage Factor	2.40	2.19	1.80	2.10	1.95	3.27	1.25	2.77	1.93	2.30
Debt to Total Capital	46.49%	42.21%	12.41%	41.96%	39.67%	42.72%	10.12%	2.45%	2.56%	44.67%
Short-Term Debt to Total Capital	0.93%	0.97%	1.44%	0.92%	0.93%	1.01%	1.72%	2.45%	2.56%	1.49%
Long-Term Debt to Total Capital	45.56%	41.25%	10.98%	41.04%	38.74%	41.72%	8.40%	0.00%	0.00%	43.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	53.51%	57.79%	87.59%	58.04%	60.33%	57.28%	89.88%	97.55%	97.44%	55.33%
Debt to EBITDA	3.09	3.10	0.64	3.41	3.31	25.61	3.04	-0.10	-0.10	-17.38
Net Debt to EBITDA	2.68	2.61	0.13	2.89	2.66	18.42	-0.60	0.66	1.09	-7.57
Long-Term Debt to EBITDA	3.03	3.03	0.57	3.34	3.23	25.01	2.52	0.00	0.00	-16.80
Debt to NOPAT	4.95	4.91	1.05	5.58	5.54	123.58	-20.17	-0.12	-0.13	-12.84
Net Debt to NOPAT	4.29	4.13	0.21	4.72	4.45	88.90	3.99	0.77	1.31	-5.60
Long-Term Debt to NOPAT	4.85	4.79	0.93	5.45	5.41	120.67	-16.74	0.00	0.00	-12.41
Altman Z-Score	1.44	1.35	1.44	1.47	1.41	1.03	1.34	0.90	1.37	1.44
Noncontrolling Interest Sharing Ratio	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.20	1.00	1.44	1.24	1.20	1.24	1.72	1.38	1.42	1.47
Quick Ratio	1.12	0.94	1.34	1.17	1.15	1.16	1.61	1.31	1.36	1.40
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,080	-997	14	62	53	57	107	818	975	306
Operating Cash Flow to CapEx	1,392.78%	1,003.62%	-1,441.88%	1,095.24%	873.26%	829.04%	-2,349.46%	1,536.21%	1,460.06%	0.00%
Free Cash Flow to Firm to Interest Expense	-113.51	-100.15	1.35	5.53	5.07	5.67	10.09	79.34	96.25	31.56
Operating Cash Flow to Interest Expense	8.76	9.92	-9.71	7.93	7.71	6.87	-11.81	10.38	9.07	13.70
Operating Cash Flow Less CapEx to Interest Expense	8.13	8.93	-10.39	7.21	6.82	6.04	-12.32	9.70	8.45	13.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.79	0.78	0.85	0.85	0.86	0.87	0.89	0.93	0.91	0.92
Accounts Receivable Turnover	7.03	6.59	6.64	6.90	7.04	7.01	7.11	7.35	7.11	7.56
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	27.14	27.50	27.25	27.43	27.41	26.79	27.14	33.04	34.29	35.06
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	51.89	55.39	54.95	52.87	51.86	52.07	51.36	49.67	51.31	48.26
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	51.89	55.39	54.95	52.87	51.86	52.07	51.36	49.67	51.31	48.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,505	1,440	936	1,519	1,480	1,305	837	591	531	1,034
Invested Capital Turnover	2.07	2.13	2.12	1.30	1.35	1.45	2.25	1.90	2.00	1.72
Increase / (Decrease) in Invested Capital	1,115	1,028	6.53	-27	-25	-135	-99	-928	-949	-271
Enterprise Value (EV)	2,039	1,783	1,264	1,767	1,579	1,237	824	520	794	1,396
Market Capitalization	1,393	1,234	1,238	1,190	1,067	781	843	635	995	1,127
Book Value per Share	$10.18	$10.73	$10.96	$11.25	$11.53	$10.11	$10.33	$8.40	$8.53	$8.91
Tangible Book Value per Share	($8.21)	($7.93)	($7.71)	($7.24)	($6.90)	($6.62)	($6.71)	($6.45)	($6.05)	($5.70)
Total Capital	1,605	1,543	1,039	1,624	1,605	1,482	953	724	752	1,383
Total Debt	746	651	129	681	637	633	96	18	19	618
Total Long-Term Debt	731	636	114	666	622	618	80	0.00	0.00	597
Net Debt	646	548	26	577	512	456	-19	-115	-201	269
Capital Expenditures (CapEx)	5.98	9.83	7.00	8.13	9.15	8.35	5.33	6.96	6.29	-1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-87	36	-12	-40	-68	80	3.59	-46	-122
Debt-free Net Working Capital (DFNWC)	87	16	139	92	85	109	196	137	174	226
Net Working Capital (NWC)	72	1.01	124	77	70	95	179	119	155	205
Net Nonoperating Expense (NNE)	4.40	1.43	6.40	6.94	6.55	46	4.16	43	6.62	5.45
Net Nonoperating Obligations (NNO)	646	548	26	577	512	456	-19	-115	-201	269
Total Depreciation and Amortization (D&A)	9.45	9.56	9.35	9.29	9.49	9.29	11	9.03	6.52	7.12
Debt-free, Cash-free Net Working Capital to Revenue	-0.67%	-4.42%	1.84%	-0.60%	-1.97%	-3.43%	4.01%	0.18%	-2.29%	-6.08%
Debt-free Net Working Capital to Revenue	4.44%	0.81%	7.03%	4.63%	4.23%	5.49%	9.79%	6.83%	8.69%	11.23%
Net Working Capital to Revenue	3.68%	0.05%	6.28%	3.88%	3.48%	4.74%	8.97%	5.95%	7.73%	10.21%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.37	$0.35	$0.17	$0.34	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37
Adjusted Weighted Average Basic Shares Outstanding	82.13M	83.47M	81.89M	82.40M	82.54M	82.20M	82.86M	83.33M	83.89M	83.33M
Adjusted Diluted Earnings per Share	$0.37	$0.35	$0.17	$0.34	$0.26	($1.50)	$0.05	($1.84)	$0.23	$0.37
Adjusted Weighted Average Diluted Shares Outstanding	82.78M	84.12M	82.32M	82.66M	82.95M	82.20M	83.28M	83.33M	84.52M	83.33M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	83.07M	83.03M	83.76M	83.94M	84.02M	84.12M	84.15M	85.87M	85.88M	85.83M
Normalized Net Operating Profit after Tax (NOPAT)	36	48	21	35	28	-76	13	27	40	58
Normalized NOPAT Margin	7.32%	9.34%	4.20%	7.04%	5.52%	-15.41%	2.54%	5.26%	7.90%	11.46%
Pre Tax Income Margin	7.93%	5.41%	4.22%	7.78%	6.09%	-27.97%	1.58%	-33.26%	4.94%	6.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.98	3.62	2.89	4.32	3.88	-11.06	1.50	-15.30	3.34	4.05
NOPAT to Interest Expense	3.69	3.12	1.98	3.14	2.69	-7.74	0.77	-10.71	2.57	3.70
EBIT Less CapEx to Interest Expense	4.35	2.63	2.22	3.59	3.00	-11.89	1.00	-15.98	2.72	4.15
NOPAT Less CapEx to Interest Expense	3.06	2.14	1.31	2.41	1.81	-8.57	0.27	-11.39	1.95	3.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	103.40%	133.44%	86.62%	23.07%	2.55%	-1.52%	-1.46%	-0.41%	-0.42%	-1.72%

Frequently Asked Questions About Pediatrix Medical Group's Financials

When does Pediatrix Medical Group's fiscal year end?

According to the most recent income statement we have on file, Pediatrix Medical Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pediatrix Medical Group's net income changed over the last 10 years?

Pediatrix Medical Group's net income appears to be on an upward trend, with a most recent value of -$99.07 million in 2024, falling from $317.20 million in 2014. The previous period was -$60.41 million in 2023. View Pediatrix Medical Group's forecast to see where analysts expect Pediatrix Medical Group to go next.

What is Pediatrix Medical Group's operating income?

Pediatrix Medical Group's total operating income in 2024 was -$68.71 million, based on the following breakdown:

Total Gross Profit: $2.01 billion
Total Operating Expenses: $2.08 billion

How has Pediatrix Medical Group revenue changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's total revenue changed from $2.44 billion in 2014 to $2.01 billion in 2024, a change of -17.5%.

How much debt does Pediatrix Medical Group have?

Pediatrix Medical Group's total liabilities were at $1.39 billion at the end of 2024, a 1.2% increase from 2023, and a 3.4% increase since 2014.

How much cash does Pediatrix Medical Group have?

In the past 10 years, Pediatrix Medical Group's cash and equivalents has ranged from $9.82 million in 2022 to $1.12 billion in 2020, and is currently $229.94 million as of their latest financial filing in 2024.

How has Pediatrix Medical Group's book value per share changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's book value per share changed from 22.55 in 2014 to 8.91 in 2024, a change of -60.5%.

Related Companies

This page (NYSE:MD) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pediatrix Medical Group (MD) Financials

Frequently Asked Questions About Pediatrix Medical Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pediatrix Medical Group (MD) Financials

Annual Income Statements for Pediatrix Medical Group

Quarterly Income Statements for Pediatrix Medical Group

Annual Cash Flow Statements for Pediatrix Medical Group

Quarterly Cash Flow Statements for Pediatrix Medical Group

Annual Balance Sheets for Pediatrix Medical Group

Quarterly Balance Sheets for Pediatrix Medical Group

Annual Metrics and Ratios for Pediatrix Medical Group

Quarterly Metrics and Ratios for Pediatrix Medical Group

Frequently Asked Questions About Pediatrix Medical Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools